Evidence map›Paper›PMID 37416766›Full record

ArticleInternational journal of biological sciences2023

A Novel Isotope-labeled Small Molecule Probe CC12 for Anti-glioma via Suppressing LYN-mediated Progression and Activating Apoptosis Pathways.

Hsu-Shan Huang, I-Tsang Chiang, Bashir Lawal, Yueh-Shan Weng, Long-Bin Jeng, Yu-Cheng Kuo, Yu-Chang Liu, Fei-Ting Hsu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hsu-Shan HuangPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; and Academia Sinica, Taipei 115, Taiwan, R.O.C.
I-Tsang ChiangDepartment of Radiation Oncology, Show Chwan Memorial Hospital, Changhua 500, Taiwan, R.O.C.
Bashir LawalPhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; and Academia Sinica, Taipei 115, Taiwan, R.O.C.
Yueh-Shan WengDepartment of Biological Science and Technology, China Medical University, Taichung 406, Taiwan, R.O.C.
Long-Bin JengOrgan Transplantation Center, China Medical University Hospital, Taichung 404, Taiwan, R.O.C.
Yu-Cheng KuoDepartment of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan, R.O.C.
Yu-Chang LiuDepartment of Radiation Oncology, Show Chwan Memorial Hospital, Changhua 500, Taiwan, R.O.C.
Fei-Ting HsuDepartment of Biological Science and Technology, China Medical University, Taichung 406, Taiwan, R.O.C.
Chang Bing Show Chwan Memorial Hospital · TWTaipei Medical University · TWUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsGlioblastomaAnimalsApoptosisCaspasesCell Line, TumorNF-kappa BTemozolomideCaspasesNF-kappa BTemozolomideAnthraquinoneCC12Epithelial-mesenchymal transitionGlioblastomaLYNMetastasis

Identifiers

PMID37416766
PMCPMC10321274
OpenAlexW4383270789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.